Thus, a prohemostatic approach targeting the PC pathway in hemophilia should be specific for APC without affecting circulating PC levels, and should be selective for APC’s anticoagulant activity without abrogating APC’s cytoprotective activities. This evidence concerns the gene APC and hemophilia.